Utility of routine evaluations for rejection in patients greater than 2 years after heart transplantation
dc.contributor.author | Golbus, Jessica R. | |
dc.contributor.author | Konerman, Matthew C. | |
dc.contributor.author | Aaronson, Keith D. | |
dc.date.accessioned | 2020-08-10T20:55:54Z | |
dc.date.available | WITHHELD_13_MONTHS | |
dc.date.available | 2020-08-10T20:55:54Z | |
dc.date.issued | 2020-08 | |
dc.identifier.citation | Golbus, Jessica R.; Konerman, Matthew C.; Aaronson, Keith D. (2020). "Utility of routine evaluations for rejection in patients greater than 2 years after heart transplantation." ESC Heart Failure 7(4): 1809-1816. | |
dc.identifier.issn | 2055-5822 | |
dc.identifier.issn | 2055-5822 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/156231 | |
dc.description.abstract | AimsGuidelines support routine surveillance testing for rejection for at least 5 years after heart transplant (HT). In patients greater than 2 years post‐HT, we examined which clinical characteristics predict continuation of routine surveillance studies, outcomes following discontinuation of routine surveillance, and the cost‐effectiveness of different surveillance strategies.Methods and resultsWe retrospectively identified subjects older than 18 who underwent a first HT at our centre from 2007 to 2016 and who survived ≥760 days (n = 217) post‐HT. The clinical context surrounding all endomyocardial biopsies (EMBs) and gene expression profiles (GEPs) was reviewed to determine if studies were performed routinely or were triggered by a change in clinical status. Subjects were categorized as following a test‐based surveillance (n = 159) or a signs/symptoms surveillance (n = 53) strategy based on treating cardiologist intent to continue routine studies after the second post‐transplant year. A Markov model was constructed to compare two test‐based surveillance strategies to a baseline strategy of discontinuing routine studies. One thousand twenty studies were performed; 835 were routine. Significant rejection was absent in 99.0% of routine EMBs and 99.8% of routine GEPs. The treating cardiologist’s practice duration, patient age, and immunosuppressive regimen predicted surveillance strategy. There were no differences in outcomes between groups. Routine surveillance EMBs cost more and were marginally less effective than a strategy of discontinuing routine studies after 2 years; surveillance GEPs had an incremental cost‐effectiveness ratio of $1.67 million/quality‐adjusted life‐year.ConclusionsAcute asymptomatic rejection is rare after the second post‐transplant year. Obtaining surveillance studies beyond the second post‐transplant year is not cost‐effective. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | Endomyocardial biopsy | |
dc.subject.other | Cost‐effectiveness | |
dc.subject.other | Gene expression profile | |
dc.subject.other | Transplantation | |
dc.title | Utility of routine evaluations for rejection in patients greater than 2 years after heart transplantation | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Cardiovascular Medicine | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/156231/2/ehf212745.pdf | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/156231/1/ehf212745_am.pdf | en_US |
dc.identifier.doi | 10.1002/ehf2.12745 | |
dc.identifier.source | ESC Heart Failure | |
dc.identifier.citedreference | Mills RM, Naftel DC, Kirklin JK, Van Bakel AB, Jaski BE, Massin EK, Eisen HJ, Lee FA, Fishbein DP, Bourge RC. Heart transplant rejection with hemodynamic compromise: a multiinstitutional study of the role of endomyocardial cellular infiltrate. Cardiac Transplant Research Database. J Heart Lung Transplant 1997; 16: 813 – 821. | |
dc.identifier.citedreference | Stehlik J, Starling RC, Movsesian MA, Fang JC, Brown RN, Hess ML, Lewis NP, Kirklin JK, Cardiac Transplant Research Database Group. Utility of long‐term surveillance endomyocardial biopsy: a multi‐institutional analysis. J Heart Lung Transplant 2006; 25: 1402 – 1409. | |
dc.identifier.citedreference | Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, Fedson S, Fisher P, Gonzales‐Stawinski G, Martinelli L, McGiffin D, Smith J, Taylor D, Meiser B, Webber S, Baran D, Carboni M, Dengler T, Feldman D, Frigerio M, Kfoury A, Kim D, Kobashigawa J, Shullo M, Stehlik J, Teuteberg J, Uber P, Zuckermann A, Hunt S, Burch M, Bhat G, Canter C, Chinnock R, Crespo‐Leiro M, Delgado R, Dobbels F, Grady K, Kao W, Lamour J, Parry G, Patel J, Pini D, Towbin J, Wolfel G, Delgado D, Eisen H, Goldberg L, Hosenpud J, Johnson M, Keogh A, Lewis C, O’Connell J, Rogers J, Ross H, Russell S, Vanhaecke J, International Society for Heart and Lung Transplantation. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29: 914 – 956. | |
dc.identifier.citedreference | Weckbach LT, Maurer U, Schramm R, Huber BC, Lackermair K, Weiss M, Meiser B, Hagl C, Massberg S, Eifert S, Grabmaier U. Lower frequency routine surveillance endomyocardial biopsies after heart transplantation. PLoS ONE 2017; 12: e0182880. | |
dc.identifier.citedreference | Crespo‐Leiro MG, Stypmann J, Schulz U, Zuckermann A, Mohacsi P, Bara C, Ross H, Parameshwar J, Zakliczynski M, Fiocchi R, Hoefer D, Colvin M, Deng MC, Leprince P, Elashoff B, Yee JP, Vanhaecke J. Clinical usefulness of gene‐expression profile to rule out acute rejection after heart transplantation: CARGO II. Eur Heart J 2016; 37: 2591 – 2601. | |
dc.identifier.citedreference | Shah KB, Flattery MP, Smallfield MC, Merinar G, Tang DG, Sheldon EH, Thacker LR, Kasirajan V, Cooke RH, Hess ML. Surveillance endomyocardial biopsy in the modern era produces low diagnostic yield for cardiac allograft rejection. Transplantation 2015; 99: e75 – e80. | |
dc.identifier.citedreference | Hamour IM, Burke MM, Bell AD, Panicker MG, Banerjee R, Banner NR. Limited utility of endomyocardial biopsy in the first year after heart transplantation. Transplantation 2008; 85: 969 – 974. | |
dc.identifier.citedreference | Moayedi Y, Foroutan F, Miller RJH, Fan CS, Posada JGD, Alhussein M, Tremblay‐Gravel M, Oro G, Luikart HI, Yee J, Shullo MA, Khush KK, Ross HJ, Teuteberg JJ. Risk evaluation using gene expression screening to monitor for acute cellular rejection in heart transplant recipients. J Heart Lung Transplant 2019; 38: 51 – 58. | |
dc.identifier.citedreference | Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, Andersen CB, Angelini A, Berry GJ, Burke MM, Demetris AJ, Hammond E, Itescu S, Marboe CC, McManus B, Reed EF, Reinsmoen NL, Rodriguez ER, Rose AG, Rose M, Suciu‐Focia N, Zeevi A, Billingham ME. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710 – 1720. | |
dc.identifier.citedreference | Agency for Health Research Quality. HCUP National Statistics on All Stays. http://hcupnet.ahrq.gov/HCUPnet.jsp. (1 October 2018). | |
dc.identifier.citedreference | Centers for Medicare & Medicaid Services. CMS physician fee schedule search. http://www.cms.gov/apps/physician-fee-schedule/search/searchcriteria.aspx. (1 October 2018). | |
dc.identifier.citedreference | Damodaran A, Dardas T, Wu AH, Dyke DB, Hummel SL, Cowger JA, Koelling TM. Changes in serial B‐type natriuretic peptide level independently predict cardiac allograft rejection. J Heart Lung Transplant 2012; 31: 708 – 714. | |
dc.identifier.citedreference | George JF, Pamboukian SV, Tallaj JA, Naftel DC, Myers SL, Foushee MT, Brown RN, Pajaro OE, McGiffin DC, Kirklin JK. Balancing rejection and infection with respect to age, race, and gender: clues acquired from 17 years of cardiac transplantation data. J Heart Lung Transplant 2010; 29: 966 – 972. | |
dc.identifier.citedreference | Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D Jr, Hsich E, Meiser B, Potena L, Robinson A, Rossano JW, Sadavarte A, Singh TP, Zuckermann A, Stehlik J, International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty‐sixth adult heart transplantation report ‐ 2019; focus theme: Donor and recipient size match. J Heart Lung Transplant 2019; 38: 1056 – 1066. | |
dc.identifier.citedreference | Klingenberg R, Koch A, Schnabel PA, Zimmermann R, Sack FU, Haass M, Dengler TJ. Allograft rejection of ISHLT grade >/=3A occurring late after heart transplantation‐‐a distinct entity? J Heart Lung Transplant 2003; 22: 1005 – 1013. | |
dc.identifier.citedreference | Lampert BC, Teuteberg JJ, Shullo MA, Holtz J, Smith KJ. Cost‐effectiveness of routine surveillance endomyocardial biopsy after 12 months post‐heart transplantation. Circ Heart Fail 2014; 7: 807 – 813. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.